Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Benitec Biopharma (BNTC) EBT Margin: 2019-2023

Historic EBT Margin for Benitec Biopharma (BNTC) over the last 2 years, with Jun 2023 value amounting to -65,114.29%.

  • Benitec Biopharma's EBT Margin was N/A to -65,114.29% in Q2 2023 from the same period last year, while for Jun 2023 it was -15,539.84%, marking a year-over-year change of. This contributed to the annual value of -25,485.33% for FY2023, which is 98396.00% down from last year.
  • Per Benitec Biopharma's latest filing, its EBT Margin stood at -65,114.29% for Q2 2023, which was down 708.69% from -8,051.85% recorded in Q1 2023.
  • In the past 5 years, Benitec Biopharma's EBT Margin ranged from a high of 8,220.00% in Q2 2020 and a low of -379,500.00% during Q1 2021.
  • Its 3-year average for EBT Margin is -101,745.00%, with a median of -40,135.71% in 2022.
  • As far as peak fluctuations go, Benitec Biopharma's EBT Margin plummeted by 37,201,786bps in 2021, and later spiked by 37,227,083bps in 2022.
  • Over the past 5 years, Benitec Biopharma's EBT Margin (Quarterly) stood at -2,719.48% in 2019, then crashed by 32,338,052bps to -326,100.00% in 2020, then surged by 30,671,600bps to -19,384.00% in 2021, then tumbled by 2,075,171bps to -40,135.71% in 2022, then plummeted by 82,269bps to -65,114.29% in 2023.
  • Its EBT Margin was -65,114.29% in Q2 2023, compared to -8,051.85% in Q1 2023 and -40,135.71% in Q4 2022.